Breast Neoplasm Female Clinical Trial
— DigiyogaCareOfficial title:
Digitally Distributed Yoga Intervention for Women Treated for Breast Cancer: Effects on Fatigue, Systemic Inflammation and Levels of Activity: A Randomized Controlled Trial
Verified date | April 2024 |
Source | Region Örebro County |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Breast cancer is the most common cancer disease in women. As the prevalence of fatigue is high in this group it is motivated to find interventions that can reduce fatigue and render in an increased level of physical activity both during and after treatment. Yoga have shown effect on cancer related fatigue (CRF) and is a rehabilitation activity that is often requested by breast cancer patients. Breast cancer patients live in cites and small-towns as well as in rural areas and therefore there is a need for accessible rehabilitation activities for all patients despite place of residence. A digitally distributed yoga class can potentially increase accessibility for those living in rural areas. Aim The overarching aim of this study is to investigate the effect of a 12-weeks digitally distributed yoga intervention for women treated for breastcancer, compared with a control group receiving regular care, concerning: - patient reported outcomes, primary endpoint CRF - systemic inflammation - activity level The study will evaluate if there are differences during and after the intervention and if those differences are sustained after 1, 3, 6, 12 and 24 months after the intervention. Additional objectives are to compare the two groups concerning completing oncologic treatment, cost effectiveness, return to work and also to describe the patients experiences of participating in a digitally distributed yoga class at home. Research questions If and how a digitally distributed yoga can influence cancer related fatigue, stress, health related quality of life and level of physical activity compared to regular care? If and how a digitally distributed yoga can have an effect on systemic inflammation? How is the feasibility of digitally distributed yoga twice weekly at home? What is the breast cancer patients' experience of participating in digitally distributed yoga clas?
Status | Active, not recruiting |
Enrollment | 229 |
Est. completion date | July 1, 2026 |
Est. primary completion date | May 1, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Clinical diagnosed with breast cancer Adult women Must have undergone breast cancer surgery with curative intention Must be Swedish speaking Must be able to read - Exclusion criteria: Metastatic disease Received neoadjuvant treatment before surgery Advanced recurrent disease Unstable cardiovascular disease Brain or bone metastasis Unstable medical condition that might be aggravated by yoga. |
Country | Name | City | State |
---|---|---|---|
Sweden | Gävle sjukhus | Gävle | |
Sweden | University Health Care Center | Örebro | |
Sweden | Västmanlands Hospital | Västerås |
Lead Sponsor | Collaborator |
---|---|
Region Örebro County | The Swedish Breast Cancer Association, Uppsala-Örebro Regional Research Council |
Sweden,
Ohlsson Nevo E, Arvidsson-Lindvall M, Hellerstedt Borjeson S, Hagberg L, Hultgren Hornqvist E, Valachis A, Wickberg A, Duberg A. Digitally distributed Yoga Intervention in Breast Cancer Rehabilitation (DigiYoga CaRe): protocol for a randomised controlled trial. BMJ Open. 2022 Nov 1;12(11):e065939. doi: 10.1136/bmjopen-2022-065939. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in physical activity | Physical activity: will be measured to be able to see changes in activity level that may be an effect of reduced fatigue and increased energy level. Measurement is carried out with an accelerometer (advanced pedometer ) for 7 days on 4 Occasion. Data on physical activity will be combined with body weight to calculate energy expenditure complemented with a diary for the same time period that describes the type of activity | Baseline is 1moths after surgery and changes at 3, 6 and 12 months after surgery | |
Other | Changes in IL-1 | Pro-inflammatory marker; blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months after surgery | |
Other | Diagnose related measurement: Side effects | Side effects from cancer treatment will be collected according to National Cancer Institute Common Toxicity Criteria. | After one and two year. | |
Other | Rate of Sick Days | From the Statistical and result database (STORE), managed by the Swedish Social Security Agency, data of sick days will be collected. | One and two years after the intervention | |
Other | Changes in IL-1ß, | Pro-inflammatory marker | Baseline is 1 months after surgery and changes are measured at 3 and 6 months | |
Other | Changes in IL-8 | Pro-inflammatory marker , blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months after surgery | |
Other | Changes in IL-12 | Pro-inflammatory marker , blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months after surgery | |
Other | Changes in Serum Hs | Inflammatory marker, blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months after surgery | |
Other | Changes in C reactive protein | Inflammatory marker,blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months after surgery | |
Other | Changes in Tumor necrosis factor -a | Inflammatory markers, blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months after surgery | |
Other | Changes in sTNFRII, | Inflammatory marker, blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months after surgery | |
Other | Changes in Fibrinogen | Inflammatory marker, blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months after surgery | |
Other | Changes in IGF-1 | Metabolic marker, blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months | |
Other | Changes in Insulin-like growth factor II (IGF-II), | Metabolic marker, blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months | |
Other | Changes in Leptin | Metabolic marker, blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months | |
Other | Changes in Adiponectin | Metabolic marker,blood sample | Baseline is 1 months after surgery and changes are measured at 3 and 6 months | |
Primary | Change in Cancer related fatigue | The Multidimensional Fatigue inventory (MFI) is a 20-item self-reported questionnaire including 5 subscales: general fatigue, physical fatigue, mental fatigue, reduced activity, and reduced motivation is a state of physical, emotional, cognitive tiredness or exhaustion related to cancer. The score can be between 20 and 100. Higher score indicate higher fatigue. | Baseline is 1 months after surgery and change after 3, 6, 24 and 48 months after breast cancer surgery | |
Secondary | Change in Stress | Instrument:The Perceived Stress Scale (PSS) measures general stress and coping capabilities. The instrument is validated on a Swedish population and has 14 questions. There are 4 alternative to each item. A higher score indicates higher stress. Each item minimum 0 and maximum 4 | Baseline is 1 months after surgery and change after 3, 6, 24 and 48 months after breast cancer surgery | |
Secondary | Change in Health related Quality of Life (HRQoL) | Instrument: European Organization for Research and Treatment of Cancer EORTC-QLQ30 . Measures generic HRQoL and comprises 30 items grouped into six multi-item scales: Global health status, Physical functioning, Role functioning, Emotional functioning, Cognitive functioning and Social functioning. Inclusive symptom scales,; nausea, pain, dyspnea , insomnia, loss of apatite, constipation and diarrhea.
Breast-23 is the breast cancer specific module for EORTC in breast cancer patients with additional 23 items. A higher score in Global health status and functioning scales indicates higher HRQL while high values in symptom scores indicates high symptom burden. Minimum is 0 and maximum is 100. |
Baseline is 1 months after surgery and change after 3, 6, 24 and 48 months after breast cancer surgery | |
Secondary | Change in Quality of life | Instrument: The EuroQol 5-dimensions is a generic standardized instrument to measure HRQoL in health economic analysis. The instrument includes five dimensions; mobility, self-care, usual activities, pain/discomfort and anxiety/depression and includes five response levels; no problems, slight problems, moderate problems, severe problems, unable to/extreme problems . Minimum 0 and maximum 4. Low values indicates higher quality of Life. | Baseline is 1 months after surgery and change after 3, 6, 24 and 48 months after breast cancer surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03980626 -
Study on Physical Activity's Relationship With Cancer and Cognition
|
N/A | |
Completed |
NCT04329819 -
Satisfaction and QUality of Life After Breast REconstruction
|
||
Recruiting |
NCT03323346 -
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03900884 -
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
|
Phase 1 | |
Completed |
NCT05042999 -
The Use of Virtual Reality During Breast Ultrasound-Guided Biopsy Procedures
|
N/A | |
Not yet recruiting |
NCT03662633 -
Diagnosis Value of SEMA4C in Breast Cancer
|
||
Recruiting |
NCT05075512 -
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04456855 -
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
|
||
Not yet recruiting |
NCT03629509 -
BEFORE Decision Aid Implementation Study
|
N/A | |
Completed |
NCT04811378 -
HaemoCerTM Application in Breast Cancer Surgery
|
N/A | |
Completed |
NCT03198442 -
Breast PET Feasibility
|
N/A | |
Not yet recruiting |
NCT05577442 -
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT04047823 -
Temperature and Injury in Radiotherapy Radiation Skin Injury
|
||
Recruiting |
NCT05452213 -
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
|
Phase 4 | |
Recruiting |
NCT05027321 -
Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies
|
N/A | |
Active, not recruiting |
NCT03425838 -
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
|
Phase 3 | |
Completed |
NCT05473026 -
Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors
|
N/A | |
Completed |
NCT04509063 -
Investigating Public Enthusiasm for Mammography Screening in Denmark
|
N/A | |
Recruiting |
NCT05711030 -
Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery
|
N/A | |
Suspended |
NCT03271853 -
Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.
|
N/A |